119 related articles for article (PubMed ID: 37619656)
1. Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer.
Ong WL; Davidson M; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Nov; 188():109864. PubMed ID: 37619656
[TBL] [Abstract][Full Text] [Related]
2. To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1153-1162. PubMed ID: 37419394
[TBL] [Abstract][Full Text] [Related]
3. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.
Alayed Y; Davidson M; Quon H; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Liu SK; Panjwani D; Helou J; Musunuru HB; Pang G; Korol R; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Commisso A; Commisso K; D'Alimonte L; Ho L; Bhounr Z; Loblaw A
Radiother Oncol; 2020 Mar; 144():135-140. PubMed ID: 31809979
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.
Elias E; Helou J; Zhang L; Cheung P; Deabreu A; D'Alimonte L; Sethukavalan P; Mamedov A; Cardoso M; Loblaw A
Radiother Oncol; 2014 Jul; 112(1):83-8. PubMed ID: 25005578
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing.
Greco C; Pares O; Pimentel N; Louro V; Nunes B; Kociolek J; Marques J; Fuks Z
Front Oncol; 2022; 12():984917. PubMed ID: 36276100
[TBL] [Abstract][Full Text] [Related]
7. Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
Alayed Y; Quon H; Ong A; Cheung P; Chu W; Chung H; Vesprini D; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Loblaw A
Radiother Oncol; 2020 Aug; 149():8-13. PubMed ID: 32416376
[TBL] [Abstract][Full Text] [Related]
8. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
Alayed Y; Davidson M; Liu S; Chu W; Tseng E; Cheung P; Vesprini D; Cheung H; Morton G; Musunuru HB; Ravi A; Korol R; Deabreu A; Ho L; Commisso K; Bhounr Z; D'Alimonte L; Mittmann N; Dragomir A; Zhang L; Loblaw A
Int J Radiat Oncol Biol Phys; 2020 May; 107(1):136-142. PubMed ID: 31987962
[TBL] [Abstract][Full Text] [Related]
11. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
12. Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
Alayed Y; Quon H; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Helou J; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Zhang L; Mamedov A; Deabreu A; Commisso A; Commisso K; Loblaw A
Radiother Oncol; 2019 Nov; 140():105-109. PubMed ID: 31265940
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients.
Fujii K; Nakano M; Kawakami S; Tanaka Y; Kainuma T; Tsumura H; Tabata KI; Satoh T; Iwamura M; Ishiyama H
Curr Oncol; 2023 May; 30(5):5062-5071. PubMed ID: 37232841
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
Musunuru HB; Quon H; Davidson M; Cheung P; Zhang L; D'Alimonte L; Deabreu A; Mamedov A; Loblaw A
Radiother Oncol; 2016 Jan; 118(1):112-7. PubMed ID: 26796591
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.
Nicholls L; Suh YE; Chapman E; Henderson D; Jones C; Morrison K; Sohaib A; Taylor H; Tree A; van As N
Clin Transl Radiat Oncol; 2020 Nov; 25():88-93. PubMed ID: 33145444
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
[TBL] [Abstract][Full Text] [Related]
18. Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial.
Alayed Y; Cheung P; Chu W; Chung H; Davidson M; Ravi A; Helou J; Zhang L; Mamedov A; Commisso A; Commisso K; Loblaw A
Radiother Oncol; 2019 Jun; 135():86-90. PubMed ID: 31015175
[TBL] [Abstract][Full Text] [Related]
19. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
[TBL] [Abstract][Full Text] [Related]
20. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
